PD-L1, Inflammation and Glioblastoma
نویسندگان
چکیده
The PD-L1 protein has an extracellular domain, a transmembrane domain and an intracellular domain. The extracellular domain (ECD) of the PD-L1 protein is comprised of IgC–like and IgV-like domains [2]. The ECD of PD-L1 interacts with the programmed death 1 (PD-1, also known as PDCD1) and B7.1 receptors. Blocking of the PD-L1 molecule with antibodies blocks cancer cells from killing cytotoxic T lymphocytes (CTLs), whereas siRNA knockdown of the PD-L1 molecule in glioblastoma makes the glioblastoma susceptible to CTL mediated killing [4,5]. Interaction with B7.1 results in the inhibition of T-lymphocyte responses in vitro and diabetogenic T-lymphocytes in vivo [6, 7].
منابع مشابه
Comprehensive analysis of PD-L1 expression in glioblastoma multiforme
Glioblastoma multiforme are highly malignant brain tumours with frequent genetic and epigenetic alterations. The poor clinical outcome of these tumours necessitates the development of new treatment options. Immunotherapies for glioblastoma multiforme including PD1/PD-L1 inhibition are currently tested in ongoing clinical trials. The purpose of this study was to investigate the molecular backgro...
متن کاملImmune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Binding of programmed death ligand-1 (PD-L1) to programmed cell death protein-1 (PD1) leads to cancer immune evasion via inhibition of T cell function. One of the defining characteristics of glioblastoma, a universally fatal brain cancer, is its profound local and systemic immunosuppression. Glioblastoma has also been shown to generate extracellular vesicles (EVs), which may play an important r...
متن کاملClinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
Programmed death 1 (PD-1, CD279) and programmed death ligand 1 (PD-L1, CD274) are involved in generating tumor-associated immunosuppression by suppression of T-cell proliferation and interleukin 2 (IL-2) production and immune checkpoint inhibitors targeting these molecules are showing compelling activity against a variety of human cancers. PD-L1 expression has shown a positive association with ...
متن کاملProgrammed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma.
In this issue of Neuro-Oncology, Berghoff et al present the results of their investigations into the expression of programmed death-ligand 1 (PD-L1) in human glioblastoma specimens and their relationship to other tissue-based and clinical parameters. In specimens from adults with newly diagnosed or recurrent glioblastoma, the investigators reported that diffuse/fibrillary PD-L1 expression of va...
متن کاملProgrammed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.
BACKGROUND Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its ligand (PD-L1) showed activity in several cancer types. METHODS We performed immunohistochemistry for CD3, CD8, CD20, HLA-DR, phosphatase and tensin homolog (PTEN), PD-1, and PD-L1 and pyrosequencing for assessment of the O6-methylguanine-methyltransferase (MGMT) promoter methylation status in 135 glioblast...
متن کامل